Vis enkel innførsel

dc.contributor.authorHjornevik, Trine
dc.contributor.authorMartinsen, Anne Catrine
dc.contributor.authorHagve, Signe Elise
dc.contributor.authorAndersen, Merethe Wigen
dc.contributor.authorMørk, Ann Cecillie
dc.contributor.authorFjeld, Jan Gunnar
dc.contributor.authorRuud, Ellen
dc.date.accessioned2016-04-20T12:01:10Z
dc.date.available2016-04-20T12:01:10Z
dc.date.issued2015-10-19
dc.identifier.citationHjornevik, T., Martinsen, A. C., Hagve, S. E., Andersen, M. W., Mørk, A. C., Fjeld, J. G., & Ruud, E. (2015). Experiences from Introducing Standardized High Dose 131I-mIBG Treatment of Children with Refractory Neuroblastoma: Differences in Effective Dose to Patients and Exposure to Caregivers. Journal of Nuclear Medicine & Radiation Therapy, 6(6), 1.en_US
dc.identifier.issn2155-9619
dc.identifier.otherFRIDAID 1330343en_US
dc.identifier.urihttp://dx.doi.org/10.4172/2155-9619.1000258
dc.identifier.urihttps://hdl.handle.net/10642/3254
dc.description.abstractAims: High dose 131I-meta iodobenzylguanidine (131I-mIBG) combined with radiosensitizing topotecan and peripheral blood stem cell support is a promising treatment regimen for children with neuroblastoma (NB). Here we present our first experiences, with particular focus on in vivo whole-body dosimetry and radiation exposure to family caregivers and hospital staff. Methods: Five children with relapsed or refractory NB were treated during 2012-2014. 131I-mIBG was administered in two fractions at two weeks apart, aiming for a total whole-body radiation-absorbed dose of 4 Gy. The 131I-mIBG activity for the 2nd administration was calculated on the basis of the measured whole-body dose following the 1st administration. Patients were isolated in a lead-shielded room, and all caregivers and staff received radiation safety training, and carried an electronic personal dosimeter. Results: The total administered activity ranged from 5.1 to 28.6 GBq (median: 22.9 GBq), resulting in effective whole-body doses ranging from 2.1 to 4.3 Gy (median: 3.8 Gy). Two out of five patients deviated from the anticipated dose exposure defined by the treatment protocol; one patient received 4.3 Gy after a single administration, and for one patient the total whole-body dose was lower than anticipated (2.1 Gy). Radiation dose to family caregivers ranged from 0.1 to 8.0 mSv. For staff members, the overall radiation dose was low, and provided no concern regarding personal dosimetry. Conclusion: High-dose 131I-mIBG treatment of children with NB has been successfully established at our institution. Radiation doses to caregivers and hospital staff are acceptable and in compliance with national and international guidelines. Two out of five patients deviated from the anticipated dose exposure, hence, accurate dosimetry-guidance during administration of high dose 131I-mIBG treatment is necessary.en_US
dc.language.isoengen_US
dc.publisherOMICS Internationalen_US
dc.relation.ispartofseriesJournal of Nuclear Medicine & Radiation Therapy;6(6)
dc.subjectNeuroblastomaen_US
dc.subjectRadionuclide therapyen_US
dc.subjectNuclear medicine therapyen_US
dc.subjectRadiation safetyen_US
dc.subjectDosimetryen_US
dc.subjectVDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Radiologi og bildediagnostikk: 763en_US
dc.titleExperiences from Introducing Standardized High Dose 131I-mIBG Treatment of Children with Refractory Neuroblastoma: Differences in Effective Dose to Patients and Exposure to Caregiversen_US
dc.typeJournal articleen_US
dc.typePeer revieweden_US
dc.description.versionCopyright: © 2015 Hjørnevik T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License; which permits unrestricted use; distribution; and reproduction in any medium; provided the original author and source are credited.en_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel